^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Title:

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

Excerpt:
Cell lines with a KRAS (V12) mutation and KRAS gains or loss (n=7) are ∼10 times more resistant than those having neither a KRAS (V12) mutation nor KRAS CNV (n=14).
DOI:
10.1038/bjc.2014.475